Quantitative prediction of the in vivo inhibition of diazepam metabolism by omeprazole using rat liver microsomes and hepatocytes

Drug Metabolism and Disposition

Volumn 32, Issue 5, 2004, Pages 572-580

  Jones, Hannah M ^a   Hallifax, David ^a   Houston, J Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; OMEPRAZOLE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DEPLETION; EVALUATION; LIVER CELL; MALE; MICROSOME; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RECEPTOR BINDING; STANDARDIZATION;

ANIMALS; BINDING SITES; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATOCYTES; KINETICS; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; OMEPRAZOLE; PREDICTIVE VALUE OF TESTS; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 2042447770     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.5.572     Document Type: Article

References (40)

1. Andersson T (1991) Omeprazole drug interaction studies. Pharmacokinet Drug Interact 21:195-212.
2. Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, and Lundborg P (1990a) Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 39:51-54.
3. Andersson T, Cederberg C, Edvardsson G, Heggelund A, and Lundborg P (1990b) Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolisers of omeprazole. Clin Pharmacol Ther 47:79-85.
4. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
5. Carlile DJ, Hakooz N, Bayliss MK, and Houston JB (1999) Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 47:625-635.
6. Chenery RJ, Ayerton A, Oldham HG, Norman SJ, and Standring P (1988) The interaction of omeprazole with rat liver cytochrome P450-mediated monooxygenase reactions in vitro and in vivo. Biochem Pharmacol 37:1407-1414.
7. Gugler R and Jensen JC (1985) Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 89:1235-1241.
8. Hallifax D, Obach RS, and Houston JB (2000) Quantitative prediction of drug inhibition: use of codeine depletion time profiles in rat microsomes and hepatocytes. Drug Metab Rev 34:226.
9. Hayes KA, Brennan B, Chenery R, and Houston JB (1995) In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. Drug Metab Dispos 23:349-353.
10. Hickman D, Wang J-P, Wang Y, and Unadkat JD (1998) Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207-215.
11. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
12. Ishigam M, Uchiyama M, Kondo T, Iwabuchi H, Inoue S, Takasaki W, Ikeda T, Komai T, Ito K, and Sugiyama Y (2001) Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Pharm Res (NY) 18:622-631.
13. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, and Sugiyama Y (1998a) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461-499.
14. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998b) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-411.
15. Kanamitsu S, Shinozaki Y, Ito K, Iwatsubo T, Suzuki H, and Sugiyama Y (2000b) Quantitative prediction of in vivo drug-drug interactions from in vitro data: effects of active transport of inhibitors into the liver. Alternative Anim Testing Exp 7:23-29.
16. Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimad N, and Sugiyama Y (2000) Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos 28:475-481.
17. Lin JH (2000) Sense and nonsense in the prediction of drug-drug interactions. Curr Drug Metab 1:305-331.
18. Lowry OH, Rosebrough HJ, Farr AL, and Randal RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
19. m values: implications for clinical correlation. J Pharmacol Exp Ther 282:391-396.
20. Margolis JM and Obach RS (2003) Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 31:606-611.
21. Neville CF, Ninomiya S, Shimad N, Kamataki T, Imaoka S, and Funae Y (1993) Characterisation of specific cytochrome P450 enzymes responsible for the metabolism of diazepam in hepatic microsomes of adult male rats. Biochem Pharmacol 45:59-65.
22. 3-hydroxylation in diazepam and nordiazepam but not N-dealkylation of diazepam and temazepam. Mol Pharmacol 37:767-774.
23. Sewell RB, Brook CW, Mihaly GW, Morgan DJ, and Smallwood RA (1994) Intracellular binding is an important determinant of the avid hepatic uptake of the high clearance drug omeprazole. Biochem Pharmacol 48:846-849.
24. Tang C, Lin Y, Rodrigues D, and Lin JH (2002) Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug Metab Dispos 30:648-654.
25. Tran TH, von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, and Greenblatt DJ (2002) Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 30:1441-1445.
26. Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Pharm Res (NY) 18:1071-1080.
27. Venkatakrishnan K, Von Moltke LL, and Greenblatt DJ (2001) Human drug metabolism and the cytochrome P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179.
28. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, and Shader RI (1994) Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268:1278-1283.
29. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
30. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, and Shader RI (1998) In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55:113-122.
31. Wang J-S, Wen X, Backman JT, and Neuvonen PJ (2002) Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of C YP2C9 by gemfibrozil in human liver microsomes. J Pharmacol Exp Ther 302:43-49.
32. Weaver RJ (2001) Assessment of drug-drug interactions: concepts and approaches. Xenobiotica 31:499-538.
33. Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, and Iga T (2001) Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution and metabolism data. Drug Metab Dispos 29:443-452.
34. Yamano K, Yamamoto K, Kotaki H, Sawada Y, and Iga T (1999a) Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver. Drug Metab Dispos 27:395-402.
35. Yamano K, Yamamoto K, Kotaki H, Takedomi S, Matsuo H, Sawada Y, and Iga T (1999b) Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome P450 in rats. Drug Metab Dispos 27:1225-1231.
36. Yamano K, Yamamoto K, Kotaki H, Takedomi S, Matsuo H, Sawada Y, and Iga T (2000) Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem and verapamil in rats: implications of concentrative uptake of inhibitors into liver. J Pharmacol Exp Ther 292:1118-1126.
37. Yao C, Kunze KL, Trager WF, Kharasch ED, and Levy RH (2003) Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metab Dispos 31:565-571.
38. Zomorodi K, Carlile DJ, and Houston JB (1995) Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. Xenobiotica 25:907-916.
39. Zomorodi K and Houston JB (1995) Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. Pharm Res (NY) 12:1642-1646.
40. Zomorodi K and Houston JB (1996) Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. Br J Clin Pharmacol 42:157-162.